Last updated: July 7, 2026

Dydrogesterone is a widely marketed oral progestogen used mainly for threatened miscarriage, recurrent miscarriage, endometriosis-associated symptoms, dysmenorrhea, and certain abnormal uterine bleeding indications. The market remains regionally fragmented with generic penetration driving price compression in higher-volume countries. Financial trajectory is shaped by (1) patent and regulatory exclusivity status that varies by country, (2) generic entry timing by formulation strength and pack size, and (3) competitive intensity among local brands and low-cost generics in Europe, Latin America, and parts of Asia.

What is the current market size and revenue trajectory for dydrogesterone?

Answer: Dydrogesterone is an established, mature product with growth tied more to demand stability in gynecology than to category expansion. Revenue growth in recent years is typically modest because volume gains are offset by price erosion from generic substitution.

Where are sales concentrated by region?

Europe: Mature progestogen market; generic competition is common in many countries.
Latin America: Mix of branded and generics; reimbursement and distribution patterns drive uneven pricing.
Asia and Middle East: Often higher brand persistence in some countries; generic penetration increases where pricing pressure accelerates.
North America: Lower commercial footprint than in Europe, reflecting narrower brand presence and competitive landscape.

What drives unit demand?

Incidence stability of key labeled conditions: threatened miscarriage, recurrent miscarriage, endometriosis-related indications, and abnormal uterine bleeding.
Persistent prescribing behavior in markets where clinicians have long-standing comfort with oral progestogens.
Diagnostic coding and guideline adherence that affect which progestogen is selected.

What drives pricing and margins?

Generic substitution speed after regulatory filings.
Local tender systems, pharmacy reimbursement rules, and wholesale pricing caps.
Pack-size strategy (e.g., tablet strength and counting) and promotion intensity in branded markets.

How do generic entry and biosimilar risk affect dydrogesterone earnings?

Answer: Biosimilar risk is not applicable because dydrogesterone is a small-molecule drug, not a biologic. Generic entry is the main earnings risk and is the dominant driver of revenue decline after exclusivity ends.

Generic substitution pathways that typically compress revenue

Rapid switching to AB-rated generics after approvals.
Competitive tender cycles that force price adjustments.
Wholesale contracting that pressures branded net prices.

What formulation and strength factors change generic competitiveness?

Dydrogesterone’s competitive set is usually organized around:

Tablet strengths and dosing regimens by indication.
Bioequivalence acceptance and manufacturing quality.
Packaging formats that influence pharmacy-level adoption.

Revenue impact pattern

Pre-generic phase: higher pricing, stable branded revenue.
Post-generic phase: revenue splits to lower-priced generics; branded share drops; total category volume may rise, but category revenue declines.

What patents protect dydrogesterone, and when do they expire?

Answer: Dydrogesterone’s core value is typically protected by legacy compound/process filings and, in some jurisdictions, by secondary patents covering specific formulations, manufacturing steps, or method-of-use. The practical market effect is that most mature countries now behave as “generic-available” markets, with the remaining protection concentrated in specific jurisdictions or in formulation/manufacturing details.

Patent estate structure (common in mature small molecules)

Active ingredient and early process patents: largely expired in major markets for decades.
Secondary patents:
- Formulation patents (e.g., specific tablet compositions or excipient systems)
- Manufacturing method patents (e.g., crystallization, granulation, drying, tablet coating)
- Method-of-use patents tied to specific regimens or diagnostic criteria

How do these patterns translate into financial trajectory?

Where secondary patents exist and are successfully enforced: slower generic erosion, higher sustained brand pricing.
Where they lapse or are not asserted: steep revenue step-down after generic launch.

What is the Orange Book status of dydrogesterone in the US?

Answer: The US regulatory status for dydrogesterone depends on currently listed drug products (brand and generic) and whether any NDA/ANDA is currently active for the specific strength, dosage form, and label.

Typical US dynamic for mature progestogens

If no current brand/NDA is actively marketed, revenue exposure in the US remains limited.
If multiple generics are listed, pricing tends to converge to low levels after early entrants.

(No Orange Book listing-level extraction is possible from the provided input alone.)

Which companies are key competitors for dydrogesterone by market?

Answer: Competition is driven by local generic manufacturers and regional branded players rather than a single global duopoly. The key commercial variable is generics’ ability to win pharmacy formularies and maintain reliable supply.

Competitive landscape by business model

Branded European incumbents: focus on clinical familiarity and guideline presence.
Regional generic leaders: compete on price, pack formats, and tender participation.
Contract manufacturers: support multiple ANDA/ANDA-like offerings via reliable tablet production.

What metrics separate winners from laggards?

Supply reliability and inventory continuity.
Wholesale rebate structures and tender execution.
Ability to launch multiple strengths or alternative pack sizes to capture shelf share.

How do price erosion and tendering affect dydrogesterone financial performance?

Answer: Price erosion is the dominant determinant of financial trajectory in mature markets. Tendering accelerates declines because manufacturers must price near the lowest eligible bid while maintaining continuity of supply.

Tender and reimbursement mechanics that shift revenue

Pharmacy margin rules: can change effective patient price and substitution rate.
Hospital formularies: tend to anchor selection for recurring prescriptions.
Government procurement: often leads to abrupt step-function declines after winner selection.

Net revenue drivers after generic pressure

Volume retention through established channels.
Switching of product mix toward less price-sensitive packs or strengths where generic penetration is lower.
Promotion intensity in markets where brand loyalty persists.

What regulatory events can shift dydrogesterone revenue in specific countries?

Answer: Label updates, market authorization renewals, pharmacovigilance restrictions, and batch-related supply interruptions can materially affect sales even for mature products.

Regulatory events to monitor

Variations in authorized indications and dosing recommendations
Risk management plan updates and safety communications
Manufacturing site inspections and resulting temporary supply constraints
Marketing authorization renewals that delay or remove certain SKUs

Financial consequences

Safety communications can reduce prescribing and trigger pharmacist substitution to alternatives.
Batch shortages can protect short-term pricing but risk losing long-term channel share.

How do method-of-use and formulation patents influence generic launch timing?

Answer: For mature small molecules, generic launch timing is often less about the primary compound and more about whether secondary IP or regulatory exclusivities delay specific strengths, regimens, or product forms.

Formulation patent scenarios

Generic approvals may proceed, but market entry for a specific tablet design or excipient composition can be constrained if patents are asserted and injunctions are imposed.
If enforcement is weak or unasserted, formula-level barriers do not prevent launch.

Method-of-use scenarios

If method-of-use claims are enforced, generics may launch but carve-out certain labeled indications, limiting revenue upside versus full-label access.

What Paragraph IV challenges exist for dydrogesterone?

Answer: For a small-molecule product with long-standing market presence, Paragraph IV exposure is often limited to specific scenarios: if a patent-protected brand/NDA still exists for the relevant dosage form and label, and if a generic filer challenges listed patents.

(No specific Paragraph IV case set is extractable from the provided input alone.)

What settlement agreements or licensing deals affect dydrogesterone market entry?

Answer: Where secondary patents exist and are listed or asserted, settlements can delay generic launch or require label carve-outs. For mature progestogens, these arrangements are usually short in duration and focused on narrow formulation or indication scope.

(No deal-level identification is possible from the provided input alone.)

Dydrogesterone vs other progestogens: how does it compare commercially?

Answer: Dydrogesterone competes against alternative oral and other progestogen therapies, including micronized progesterone formulations and other progestogens used for similar gynecologic indications. Commercial outcomes depend on prescriber preference, perceived clinical evidence, and payer adoption.

What typically differentiates dydrogesterone in the market?

Oral dosing convenience and long clinical familiarity.
Branding and guideline integration in certain European markets.
Pack and strength availability for standard regimen adherence.

Where competition is strongest

Markets where guidelines recommend competing progestogens interchangeably.
Tender-driven systems that choose the lowest price for an equivalent therapy class.

Revenue implication

Category growth is usually limited; market share swings create most of the revenue variability.

What generic entry risks exist for dydrogesterone?

Answer: Generic entry risk is primarily about speed and breadth of substitution across strengths. The most material risk is not “whether” generics can enter, but how quickly they capture pharmacy and payer share after approvals.

Key risk channels

Multiple generic entrants reduce branded share quickly.
Broad label acceptance for generics reduces carve-out protection.
Regulatory approvals in parallel across jurisdictions shorten the period of brand price premium.

How does manufacturing/IP complexity act as a barrier to entry?

Answer: For tablet-based small molecules, manufacturing barriers are typically lower than for biologics, but quality and batch consistency still determine brand-generic switching.

What matters for production continuity

Consistent tablet hardness and dissolution profiles.
Raw material sourcing robustness.
Site compliance and inspection history.

Financial impact

Reliable generics gain share; recurring supply disruptions increase pricing volatility and allow incumbent recovery, but typically not long-term.

Key timelines to map for dydrogesterone exclusivity and financial inflection

Answer: The financial trajectory is best modeled around country-level exclusivity status and the first generic approvals after those periods end.

Timeline framework for investment and licensing decisions

Identify last relevant IP or regulatory exclusivity per jurisdiction and SKU.
Track ANDA/marketing application approvals for AB-equivalent products.
Monitor launch date, number of entrants, and price index behavior post-launch.
Model revenue split shift from branded to generics based on formulary/tender schedules.

(No jurisdiction-specific expiration dates can be provided from the provided input alone.)

Key Takeaways

Dydrogesterone’s market is mature; financial performance is dominated by generic substitution and price erosion rather than new pipeline-driven growth.
No biosimilar risk applies; the primary IP and regulatory risk is country-level secondary patents and formulation/label protection that can delay or limit generic uptake.
Earnings trajectory is typically characterized by stable demand with declining price and margin after generic entry, with regional variability driven by tendering, reimbursement, and brand persistence.
Commercial strategy focuses on volume defense through channel execution (pack/strength coverage, supply reliability) and minimizing branded net price erosion where secondary IP or label breadth can be defended.

FAQs

How quickly do dydrogesterone prices fall after generic launches in Europe?
Do formulation-only patents for dydrogesterone typically delay generic entry or only restrict specific SKUs?
Which gynecology indications most affect dydrogesterone prescribing and switching to alternative progestogens?
What supply chain events most often disrupt dydrogesterone availability and create short-term price spikes?
How should investors model revenue exposure for dydrogesterone in countries with active tender procurement?

References

(No citable sources were provided in the prompt; no external sources are included.)

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	55
DailyMed Link:	DYDROGESTERONE at DailyMed

Sponsor	Phase
Women's Hospital School Of Medicine Zhejiang University	PHASE1
Mỹ Đức Hospital	NA
Bedaya Hospital	PHASE2

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Solvay	GYNOREST	dydrogesterone	TABLET;ORAL	017388-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Solvay	GYNOREST	dydrogesterone	TABLET;ORAL	017388-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Summary for DYDROGESTERONE

Recent Clinical Trials for DYDROGESTERONE

Medical Subject Heading (MeSH) Categories for DYDROGESTERONE

Anatomical Therapeutic Chemical (ATC) Classes for DYDROGESTERONE